Short answer
Humacyte, Inc. (HUMA) filed its Q2 2026 10-Q quarterly report on Aug 12, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $406,000 (up 34.9% year over year) with net income of −$37M.
Q2 2026 key financials · XBRL
- Revenue
- $406,000
- +34.9% YoY · −18.0% QoQ
- Net income
- −$37M
- +2.3% YoY · −108.9% QoQ
- Operating margin
- -6649.3%
- EPS (diluted)
- −$0.16
- +40.7% YoY · −77.8% QoQ
Source: XBRL data from the Humacyte, Inc. (HUMA) Q2 2026 10-Q on SEC EDGAR. USD.
Humacyte, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0.4M, up 35% YoY from $0.3M; Symvess product revenue $0.4M vs $0.1M
- Operating loss $27.0M vs $29.7M; operating margin -6,649.3% vs -9,875.4% YoY
- Worst cost impact: cost of goods sold $1.2M vs $0.2M, including $0.7M inventory reserve
- Cash $79.9M plus restricted cash $0.4M; operating cash outflow $47.2M for six months
- $53.8M net proceeds from equity offering; workforce reductions expected to save $14.3M
Risk Factors
- Workforce reduction: May 2026 plan eliminated approximately 45 employees and deferred planned hires
- Nasdaq compliance: $1.00 minimum bid-price deficiency triggered a 180-day cure period through January 27, 2027
- Delisting risk: Failure to regain compliance could impair liquidity and access to additional capital
- Cost-saving execution: Severance costs and employee attrition could reduce cash flows and disrupt productivity
- Equity dilution: Mayo Clinic received warrants for 240,000 shares at a $1.11 exercise price
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Humacyte, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.